Directive 2012/5/EU of the European Parliament and of the CouncilDangos y teitl llawn

Article 1 U.K.

Directive 2000/75/EC is hereby amended as follows:

(1)

in Article 2, the following point is added:

‘(j) “live attenuated vaccines”

:

vaccines which are produced by adapting bluetongue virus field isolates through serial passages in tissue culture or in embryonated hens’ eggs.’;

(2)

Article 5 is replaced by the following:

‘Article 5

1. The competent authority of a Member State may decide to allow the use of vaccines against bluetongue provided that:

(a) such decision is based on the result of a specific risk assessment carried out by the competent authority;

(b) the Commission is informed before such vaccination is carried out.

2. Whenever live attenuated vaccines are used, Member States shall ensure that the competent authority demarcates:

(a) a protection zone, consisting of at least the vaccination area;

(b) a surveillance zone, consisting of a part of the Union territory with a depth of at least 50 kilometres extending beyond the limits of the protection zone.’;

(3)

in Article 6(1), point (d) is replaced by the following:

‘(d)

implement the measures adopted in accordance with the procedure laid down in Article 20(2), in particular with regard to the introduction of any vaccination programme or other alternative measures;’;

(4)

in Article 8(2), point (b) is replaced by the following:

‘(b)

The surveillance zone shall consist of a part of the Union territory with a depth of at least 50 kilometres extending beyond the limits of the protection zone and in which no vaccination against bluetongue with live attenuated vaccines has been carried out during the previous 12 months.’;

(5)

in Article 10, point 2 is replaced by the following:

‘2.

any vaccination against bluetongue using live attenuated vaccines is prohibited in the surveillance zone.’.